shingrix
glaxosmithkline biologicals sa - recombinant varicella zoster virus glycoprotein e - ristil - bóluefni - shingrix is indicated for prevention of herpes zoster (hz) and post-herpetic neuralgia (phn), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of hz. notkun shingrix ætti að vera í samræmi við opinbera tillögur.
blenrep
glaxosmithkline (ireland) limited - belantamab mafodotin - mergæxli - Æxlishemjandi lyf - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
jemperli
glaxosmithkline (ireland) limited - dostarlimab - endometrial neoplasms - antineoplastic agents and antibody drug conjugates - jemparli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dmmr)/microsatellite instability-high (msi h) recurrent or advanced endometrial cancer (ec) that has progressed on or following prior treatment with a platinum-containing regimen.
havrix stungulyf, dreifa 1440 elisa ein./ml
glaxosmithkline pharma a/s - lifrarbólguveira a (deydd) - stungulyf, dreifa - 1440 elisa ein./ml
bactroban smyrsli 20 mg/g
glaxosmithkline pharma a/s - mupirocinum inn - smyrsli - 20 mg/g
bactroban nasal nefsmyrsli 20 mg/g
glaxosmithkline pharma a/s - mupirocinum kalsíum - nefsmyrsli - 20 mg/g
betnovat húðlausn 1 mg/ml
glaxosmithkline pharma a/s - betamethasonum valerat - húðlausn - 1 mg/ml
dermovat húðlausn 0,5 mg/ml
glaxosmithkline pharma a/s - clobetasolum própíónat - húðlausn - 0,5 mg/ml
dermovat smyrsli 0,5 mg/g
glaxosmithkline pharma a/s - clobetasolum própíónat - smyrsli - 0,5 mg/g
flutivate (cutivat) smyrsli 0,005 %
glaxosmithkline pharma a/s - fluticasonum própíónat - smyrsli - 0,005 %